PSA and second-line therapy of hormone refractory prostate carcinoma

Carlo Pavone, Darvinio Melloni, Vincenzo Serretta, Rizzo, Contino, Vincenzo Serretta, Giuseppe Pomara

Risultato della ricerca: Articlepeer review

2 Citazioni (Scopus)

Abstract

The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was <4 ng/ml. Eight patients (33%) only had a subjective response. However, 75% of the patients with a PSA value <4 ng/ml had a subjective improvement. On the other hand, subjective response was 25% only in patients in whom PSA value decreased to <50% of the initial value but >4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.
Lingua originaleEnglish
pagine (da-a)131-134
Numero di pagine4
RivistaUrologia Internationalis
Volume66
Stato di pubblicazionePublished - 2001

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Entra nei temi di ricerca di 'PSA and second-line therapy of hormone refractory prostate carcinoma'. Insieme formano una fingerprint unica.

Cita questo